Display options
Cite
Ravegnini G, De Iaco P, Gorini F, et al. Role of Circulating miRNAs in Therapeutic Response in Epithelial Ovarian Cancer: A Systematic Revision. Biomedicines. 2021;9(10)doi: 10.3390/biomedicines9101316.
Ravegnini, G., De Iaco, P., Gorini, F., Dondi, G., Klooster, I., De Crescenzo, E., Bovicelli, A., Hrelia, P., Perrone, A. M., & Angelini, S. (2021). Role of Circulating miRNAs in Therapeutic Response in Epithelial Ovarian Cancer: A Systematic Revision. Biomedicines, 9(10), . https://doi.org/10.3390/biomedicines9101316
Ravegnini, Gloria, et al. "Role of Circulating miRNAs in Therapeutic Response in Epithelial Ovarian Cancer: A Systematic Revision." Biomedicines vol. 9,10 (2021). doi: https://doi.org/10.3390/biomedicines9101316
Ravegnini G, De Iaco P, Gorini F, Dondi G, Klooster I, De Crescenzo E, Bovicelli A, Hrelia P, Perrone AM, Angelini S. Role of Circulating miRNAs in Therapeutic Response in Epithelial Ovarian Cancer: A Systematic Revision. Biomedicines. 2021 Sep 26;9(10). doi: 10.3390/biomedicines9101316. PMID: 34680433; PMCID: PMC8533254.
Copy Download .nbib Format: NLM
Share it on

Biomedicines. 2021 Sep 26;9(10). doi: 10.3390/biomedicines9101316.

Role of Circulating miRNAs in Therapeutic Response in Epithelial Ovarian Cancer: A Systematic Revision.

Biomedicines

Gloria Ravegnini, Pierandrea De Iaco, Francesca Gorini, Giulia Dondi, Isabella Klooster, Eugenia De Crescenzo, Alessandro Bovicelli, Patrizia Hrelia, Anna Myriam Perrone, Sabrina Angelini

Affiliations

  1. Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.
  2. Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
  3. Department of Medical and Surgical Sciences, DIMEC, University of Bologna, 40138 Bologna, Italy.
  4. Centro di Studio e Ricerca delle Neoplasie Ginecologiche, University of Bologna, 40138 Bologna, Italy.
  5. Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

PMID: 34680433 PMCID: PMC8533254 DOI: 10.3390/biomedicines9101316

Abstract

Epithelial ovarian cancer (EOC) is one of the most lethal cancers worldwide, mostly due to nonspecific symptoms and a lack of screening tests, which, taken together, contribute to delayed diagnosis and treatment. The current clinical biomarker is serum CA-125, which allows the identification of most advanced primary and relapsed disease and correlates with disease burden; however, as well highlighted in the literature, CA-125 often lacks sensitivity and specificity, and is not helpful in monitoring chemotherapeutic response or in predicting the risk of relapse. Given that, the identification of novel biomarkers able to foster more precise medical approaches and the personalization of patient management represents an unmet clinical requirement. In this context, circulating miRNAs may represent an interesting opportunity as they can be easily detected in all biological fluids. This is particularly relevant when looking for non-invasive approaches that can be repeated over time, with no pain and stress for the oncological patient. Given that, the present review aims to describe the circulating miRNAs currently identified as associated with therapeutic treatments in OC and presents a complete overview of the available evidence.

Keywords: chemotherapy; circulating miRNAs; drug response; epithelial ovarian cancer; liquid biopsy; ovarian cancer; personalized medicine

References

  1. Oncotarget. 2015 Nov 3;6(34):36815-24 - PubMed
  2. Chin Clin Oncol. 2020 Aug;9(4):47 - PubMed
  3. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 - PubMed
  4. Cancer Cell. 2020 Apr 13;37(4):485-495 - PubMed
  5. Cancers (Basel). 2021 Mar 15;13(6): - PubMed
  6. Bioengineered. 2020 Dec;11(1):311-317 - PubMed
  7. Oncol Rep. 2021 May;45(5): - PubMed
  8. Theranostics. 2020 Mar 15;10(10):4544-4556 - PubMed
  9. Clin Chem. 2020 Feb 1;66(2):352-362 - PubMed
  10. Int J Cancer. 2021 Feb 1;148(3):528-545 - PubMed
  11. J Exp Clin Cancer Res. 2019 Feb 15;38(1):81 - PubMed
  12. Gynecol Oncol. 2010 Oct;119(1):7-17 - PubMed
  13. Front Oncol. 2021 Jul 08;11:703949 - PubMed
  14. Expert Rev Mol Diagn. 2017 Mar;17(3):209-215 - PubMed
  15. Biomed Res Int. 2014;2014:934261 - PubMed
  16. Trends Genet. 2016 Jun;32(6):360-371 - PubMed
  17. PLoS One. 2013;8(3):e60134 - PubMed
  18. Nat Commun. 2014;5:2977 - PubMed
  19. Toxicol Sci. 2015 Nov;148(1):2-13 - PubMed
  20. Ann Surg Oncol. 2012 Oct;19(11):3522-7 - PubMed
  21. Cancer Sci. 2017 May;108(5):886-896 - PubMed
  22. Eur J Cancer. 2017 Aug;81:66-73 - PubMed
  23. J Oncol. 2010;2010:932371 - PubMed
  24. Br J Cancer. 2014 Feb 18;110(4):976-83 - PubMed
  25. Cell Physiol Biochem. 2016;39(2):501-10 - PubMed
  26. J Ovarian Res. 2018 Sep 15;11(1):81 - PubMed
  27. Gynecol Oncol. 2011 Jan;120(1):56-62 - PubMed
  28. Microrna. 2020;9(1):49-57 - PubMed
  29. Obstet Gynecol. 2021 Jan 1;137(1):108-121 - PubMed
  30. Dis Markers. 2017;2017:3098542 - PubMed
  31. Gynecol Oncol. 2021 Jun;161(3):884-895 - PubMed
  32. Gynecol Oncol. 2017 Jul;146(1):137-145 - PubMed
  33. EMBO Mol Med. 2012 Mar;4(3):143-59 - PubMed
  34. World J Biol Chem. 2017 Feb 26;8(1):45-56 - PubMed
  35. Mol Cancer. 2008 Apr 28;7:35 - PubMed
  36. Int J Mol Sci. 2018 Sep 21;19(10): - PubMed
  37. Minerva Med. 2020 Apr;111(2):133-140 - PubMed
  38. Ann Oncol. 2018 Feb 1;29(2):311-323 - PubMed
  39. Front Oncol. 2018 Dec 21;8:654 - PubMed
  40. Cancer Res. 2013 Jan 15;73(2):473-7 - PubMed
  41. Syst Rev. 2015 Jan 01;4:1 - PubMed
  42. FEBS Lett. 2007 Mar 6;581(5):795-9 - PubMed
  43. Clin Chem. 2014 Jan;60(1):206-13 - PubMed
  44. Transl Lung Cancer Res. 2016 Aug;5(4):420-3 - PubMed
  45. Int J Cancer. 2011 May 15;128(10):2274-83 - PubMed
  46. Mol Oncol. 2021 Jan;15(1):67-79 - PubMed
  47. Cancers (Basel). 2019 Jan 08;11(1): - PubMed
  48. Diagnostics (Basel). 2021 Apr 14;11(4): - PubMed
  49. Am J Obstet Gynecol. 2013 Nov;209(5):462.e1-462.e11 - PubMed
  50. PLoS One. 2015 Oct 20;10(10):e0141279 - PubMed
  51. Sci Rep. 2019 Apr 5;9(1):5668 - PubMed
  52. Cancers (Basel). 2019 Jun 17;11(6): - PubMed
  53. Ther Drug Monit. 2019 Apr;41(2):115-120 - PubMed
  54. Appl Nurs Res. 2002 Aug;15(3):197-8 - PubMed
  55. Mol Cancer. 2018 Oct 11;17(1):147 - PubMed
  56. PLoS One. 2014 May 27;9(5):e97094 - PubMed
  57. Cancers (Basel). 2019 Jan 20;11(1): - PubMed
  58. Nat Rev Cancer. 2011 Jun 24;11(7):467-80 - PubMed
  59. Cancer Res. 2012 May 1;72(9):2197-205 - PubMed
  60. NPJ Precis Oncol. 2018 Sep 17;2:20 - PubMed
  61. Biomed Rep. 2016 Oct;5(4):395-402 - PubMed
  62. Mini Rev Med Chem. 2015;15(6):467-74 - PubMed
  63. Clin Chem Lab Med. 2019 Jun 26;57(7):1053-1062 - PubMed
  64. Biochimie. 2019 Dec;167:12-24 - PubMed
  65. Gynecol Oncol. 2020 Oct;159(1):256-263 - PubMed
  66. Future Oncol. 2008 Apr;4(2):289-98 - PubMed
  67. Int J Cancer. 2013 Jan 15;132(2):E48-57 - PubMed
  68. J Ovarian Res. 2020 Oct 19;13(1):124 - PubMed

Publication Types